Search

News Physical Activity in Young Men with Hemophilia A

What may influence the inclusion of physical activity in the lifestyle of individuals with hemophilia? This was the focus of a Norwegian study published in the journal Haemophilia.

Source: Hemophilia with Movement 6. 10. 2023

News Model of Risk of Bleeding Associated with Physical Activity in Hemophiliacs with Factor and Non-Factor Treatment

In the treatment of hemophilia A, both FVIII concentrate replacement therapy and non-factor therapy are available today. However, there is no clinical data comparing the risk of bleeding associated with physical activity between factor and non-factor treatments. In this situation, one approach is to model possible scenarios and attempt to indirectly compare different modalities of bleeding prevention.

Source: Hemophilia 18. 5. 2023

Články časopisu Prospective, multicentric, non-interventional study to assess the existing treatment of type 2 diabetes mellitus patients inadequately controlled with metformin monotherapy –⁠ KOMETA CZ

Author of the article: Š. Svačina, V. Veselá Source: Vnitřní lékařství | 12/2013 16. 12. 2013

Články časopisu Personalized medicine in haematooncology –⁠ the pathologist’s perspective

Author of the article: Vít Campr Source: Časopis lékařů českých | 10/2010 16. 10. 2010

News New Antidiabetic Drugs in Cardiovascular Prevention in International Recommendations

Results from studies on new antidiabetic drugs showing cardiovascular (CV) benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i, gliflozins) and glucagon-like peptide 1 receptor agonists (GLP-1RA) have led to efforts to create new recommendations for their use in patients with type 2 diabetes mellitus (T2DM) for primary and secondary CV disease prevention. A recent review by American experts succinctly summarizes what current guidelines from American and European professional societies say on this subject.

Source: Diabetes 20. 12. 2021

News Fresh data from real clinical practice on targeted treatment of RA with etanercept: Should therapy be changed after 12 weeks due to insufficient response?

A recently published German study investigated, among other things, what percentage of patients with rheumatoid arthritis (RA) achieve remission or low disease activity after a certain period of etanercept treatment in real clinical practice.

Source: Arthritis 24. 11. 2022

News Brigatinib in the Therapy of ALK-Positive NSCLC –⁠ First Results of the J-ALTA Study

Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor with broad and potent activity against ALK gene mutations causing resistance to ALK inhibitor therapy (ALKi). In patients refractory to crizotinib therapy, brigatinib administration in phase III clinical trials led to high systemic and intracranial therapeutic responses and concurrently improved median progression-free survival (PFS). The primary analysis objective of the phase II J-ALTA clinical study, presented at this year's American Society of Clinical Oncology (ASCO) congress, was to assess the efficacy and safety of therapy in patients with ALK-positive NSCLC naïve to previous ALKi therapy.

Source: Non-Small Cell Lung Cancer 9. 9. 2021

News Changes in Blood Count as Possible Prognostic Markers of Response to Panitumumab in Patients with mCRC

As part of the VALENTINO study with panitumumab in patients with metastatic colorectal cancer without RAS mutation, the connection between certain blood count parameters associated with inflammation and patient prognosis was investigated.

Source: Colorectal Cancer 16. 6. 2020

News Cannabidiol as a way to reduce anxiety in patients with Parkinson's disease?

A recent study by Brazilian authors examined the effects of cannabidiol on tremors and anxiety in patients with Parkinson's disease. Could it represent a promising modality in this indication?

Source: 27. 5. 2020

News Sports in People with Hemophilia –⁠ Possible and Safe

Active involvement in sports and an active lifestyle are important aspects of daily functioning for people with hemophilia. Modern treatment of this disease, including the prophylactic administration of concentrates of the missing coagulation factor, has led to an increase in the number of very active patients. Numerous studies have confirmed that they are as physically active as the general population, although some emphasize that this is more relevant to children and young people. Therefore, the work of Dutch and Swedish authors focused on examining the relationship between age and physical activity in hemophiliacs, especially with regard to more intensive and riskier sports.

Source: Hemophilia with Movement 19. 6. 2023

News Turoctocog Alfa in Tertiary Prophylaxis of Hemophilia A or Is It Always About Bleeding? Case Studies

This case report from our own practice concerns our experience with the treatment of hemophilia A with turoctocog alfa. The intention is, among other things, to compare different outcomes in our two patients regarding their self-assessment of bleeding without objective validation.

Source: Hemophilia with Movement 19. 8. 2022

News Brief from ASH 2021: News and Advances in CLL Treatment

The summary from the first day of the 63rd American Society of Hematology (ASH) Congress in Atlanta in December 2021 brought several new advancements in the treatment of chronic lymphocytic leukemia (CLL). Dr. Brian Koffman from the CLL Society provided commentary on these developments.

Source: Chronic Lymphocytic Leukemia 12. 4. 2022

News Ixekizumab administered for 5 years demonstrated high efficacy and a favorable safety profile in patients with moderate to severe psoriasis

Ixekizumab is a recombinant humanized monoclonal antibody against interleukin 17A, indicated for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. At the 24th World Congress of Dermatology in Milan in June 2019, results were presented from a study evaluating the efficacy and safety of long-term administration of ixekizumab.

Source: Biological Treatment 19. 5. 2020

News Safety of Riociguat in the Treatment of Thromboembolic Pulmonary Hypertension in Common Practice

In March 2021, the final safety results of riociguat in the treatment of thromboembolic pulmonary arterial hypertension in real-world practice were published from the international EXPERT registry, which also included Czech patients. The safety profile of the therapy was consistent with the findings of previous clinical studies.

Source: Pulmonary hypertension (CTEPH, PAH) 16. 5. 2021

News Pain Relief and Functional Score Improvement in Patients with Low Rheumatoid Arthritis Activity: Baricitinib vs. Adalimumab

In patients with rheumatoid arthritis, pain and functional impairment may persist even with good disease activity control. An exploratory analysis of the RA-BEAM study compared the effects of baricitinib, adalimumab, and placebo added to methotrexate on residual pain and functional scores in patients with rheumatoid arthritis (RA) who achieved remission or low disease activity with this treatment.

Source: Biological Treatment 20. 2. 2020